Results 211 to 220 of about 232,408 (333)

Recent Developments in Nanoparticle‐Hydrogel Hybrid Materials for Controlled Release

open access: yesAdvanced Science, EarlyView.
This review highlights recent advances in nanoparticle–hydrogel hybrid materials for controlled drug delivery. It explores diverse nanocarrier–hydrogel combinations, drug loading strategies, release mechanisms, and stimuli‐responsive behaviors. Emphasis is placed on the molecular interactions driving hybrid material performance, offering insights into ...
Yiping Fan   +8 more
wiley   +1 more source

Clinicopathological background of local recurrence in high grade sarcoma of the extremity with preoperative chemotherapy: a supplementary analysis of JCOG0304. [PDF]

open access: yesJpn J Clin Oncol
Tsukushi S   +19 more
europepmc   +1 more source

Atrial Fibroblasts‐Derived Extracellular Vesicles Exacerbate Atrial Arrhythmogenesis

open access: yesAdvanced Science, EarlyView.
Exosome miR‐224‐5p derived from angiotensin II‐treated atrial fibroblasts creates a substrate for AF by promoting atrial electrical remodeling. Increased exosome miR‐224‐5p enhances AF susceptibility by inhibiting CACNA1c expression and decreasing ICa current of atrial cardiomyocytes.
Yue Yuan   +13 more
wiley   +1 more source

Solitary Fibrous Tumor of the Right Elbow: A Case Report. [PDF]

open access: yesCureus
Mach M   +4 more
europepmc   +1 more source

Long Non‐Coding RNA IGFRIL Couples with PTBP1 to Destabilize IGFBP3 mRNA to Promote the IGF1R‐AKT‐mTOR Axis and Hepatocellular Carcinoma

open access: yesAdvanced Science, EarlyView.
The limited understanding of IGFR pathway activation hinders its clinical application in HCC. Here, IGFRIL is identified as a novel non‐coding activator of the IGF1R, which recruits PTBP1 to destabilize IGFBP3 mRNA and activates IGF1R, and proposes IGFRIL as a novel actionable target for HCC patients.
Jing Zhang   +28 more
wiley   +1 more source

Alternative Models for Anticancer Drug Discovery From Natural Products Using Binary Tumor‐Microenvironment‐on‐a‐Chip

open access: yesAdvanced Science, EarlyView.
This study presents a binary tumor‐microenvironment‐on‐a‐chip (T‐MOC) system incorporating multicellular tumor spheroids (MCTs) as an alternative preclinical platform to evaluate the efficacy of anticancer natural products. The T‐MOC model reproduces in vivo drug delivery barriers and physiological conditions, enabling morphological analysis to predict
Youngwon Kim   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy